Nivalis Therapeutics Inc (NASDAQ:NVLS) has been assigned a consensus rating of “Hold” from the eight analysts that are currently covering the firm. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $5.63.
Several equities analysts recently issued reports on the company. Cowen and Company restated a “hold” rating on shares of Nivalis Therapeutics in a research report on Wednesday. Zacks Investment Research upgraded Nivalis Therapeutics from a “hold” rating to a “buy” rating and set a $3.00 price target on the stock in a research report on Wednesday. Finally, Vetr cut Nivalis Therapeutics from a “hold” rating to a “sell” rating and set a $2.50 price target on the stock. in a research report on Monday, February 27th.
A number of institutional investors have recently added to or reduced their stakes in NVLS. Sphera Funds Management LTD. acquired a new position in Nivalis Therapeutics during the third quarter valued at about $1,664,000. Perceptive Advisors LLC acquired a new position in Nivalis Therapeutics during the fourth quarter valued at about $274,000. Endurant Capital Management LP boosted its position in Nivalis Therapeutics by 29.8% in the third quarter. Endurant Capital Management LP now owns 85,412 shares of the biotechnology company’s stock valued at $694,000 after buying an additional 19,629 shares during the last quarter. Finally, Spark Investment Management LLC acquired a new position in Nivalis Therapeutics during the third quarter valued at about $145,000. Institutional investors own 75.85% of the company’s stock.
Shares of Nivalis Therapeutics (NASDAQ:NVLS) traded down 6.33% on Monday, reaching $2.22. The company had a trading volume of 126,553 shares. The company’s market capitalization is $34.76 million. The company has a 50 day moving average of $2.81 and a 200-day moving average of $3.68. Nivalis Therapeutics has a 52 week low of $2.00 and a 52 week high of $9.35.
Nivalis Therapeutics (NASDAQ:NVLS) last issued its quarterly earnings results on Monday, February 13th. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.55) by $0.05. During the same period last year, the firm posted ($0.42) earnings per share. Analysts predict that Nivalis Therapeutics will post ($1.16) earnings per share for the current fiscal year.
About Nivalis Therapeutics
Nivalis Therapeutics, Inc is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.
Receive News & Ratings for Nivalis Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.